Author:
Schoemaker N E,van Kesteren C,Rosing H,Jansen S,Swart M,Lieverst J,Fraier D,Breda M,Pellizzoni C,Spinelli R,Porro M Grazia,Beijnen J H,Schellens J H M,ten Bokkel Huinink W W
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105–119
2. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245–259
3. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethyulene glycol via a glycine linker. Cancer Chemother Pharmacol 42: 407–414
4. Conover CD, Greenwald RB, Pendri A, Sum K (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-cancer Drug Design 14: 499–506
5. Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours. Cancer Chemother Pharmacol 36: 393–403
Cited by
114 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献